ContraVir Pharmaceuticals Announces the Approval of the IND and Initiation of the Clinical Development Program of CRV431 in the United States Biotech Investing
Rhythm Pharmaceuticals Completes Pivotal Enrollment in Two Ongoing Phase 3 Clinical Trials Pharmaceutical Investing
Arsanis Out-Licenses Preclinical Stage Klebsiella pneumoniae Monoclonal Antibodies from ASN300 Program Biotech Investing
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for GARDASIL 9 Pharmaceutical Investing
FDA Approves Merck’s KEYTRUDA (pembrolizumab) for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Pharmaceutical Investing
scPharmaceuticals Receives Complete Response Letter from the FDA for FUROSCIX Pharmaceutical Investing
Actinium Pharmaceuticals Announces Treatment of First Patient in Novel Combination Trial of Actimab-A Plus CLAG-M Pharmaceutical Investing
Corium Announces Issuance of Key U.S. Patent Covering Corplex Donepezil Transdermal System for Alzheimer’s Disease Biotech Investing
Xanthic Announces the Installation of Manufacturing Equipment at its Strategic Partner’s Oregon Facility Cannabis Investing News
